Immune response to 19A serotype after immunization of 19F containing pneumococcal conjugate vaccine in Korean children aged 12-23 months by Lee, Hyun Ju et al.
DOI: 10.3345/kjp.2011.54.4.163 
Korean J Pediatr 2011;54(4):163-168
Original article
163
Immune response to 19A serotype after immunization 
of 19F containing pneumococcal conjugate vaccine 
in Korean children aged 12-23 months 
Purpose: The purpose of this study was to evaluate the immune 
response to serotype 19A in children aged 12-23 months after 
immunization of the 19F containing 7-valent pneumococcal conjugate 
vaccine (PCV7).
Methods: Blood samples from a total of 45 subjects (age 12-23 months) 
were included in the study. Subjects were categorized according to 
immunization status into three groups as follows: 18 subjects with 3 
primary doses and 1 booster dose of PCV7 (booster group), 21 subjects 
with 3 primary doses before 12 months of age (primary group), and 6 
subjects with no vaccination history of PCV7 (control group). An ELISA 
and opsonophagocytic killing assay (OPKA) was done to evaluate the 
immune responses against serotypes 19F and 19A.
Results: According to the ELISA, all subjects had antibody titers ≥0.35 
µg/mL for serotypes 19F and 19A in the booster and primary group 
and 83.0% and 66.7% in the control group, respectively. According to 
the OPKA, subjects with opsonic activity (≥20) against serotypes 19F 
and 19A were 100% and 61.1% of the subjects in the booster group 
and 66.7% and 19.0% in the primary group, respectively. No subjects 
in the control group had opsonic antibodies against both serotypes.
Conclusion: In conclusion, in children 12-23 months age who were 
previously vaccinated with PCV7, a cross-reactive immune response is 
elicited against serotype 19A after a primary series of 3 doses in a small 
proportion of subjects, and this response is amplified after booster 
vaccination. 
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Introduction
Streptococcus pneumoniae is an important bacterial pathogen 
which is a major cause of morbidity and mortality in children, the 
elderly and immunocompromised subjects of all ages. S. pneumoniae 
was the most common cause of invasive bacterial infections in 
children and it is a common cause of acute otitis media, sinusitis, and 
community-acquired pneumonia
1). Moreover, S. pneumoniae is a 
leading cause for use of antimicrobial agents in clinical practice. 
To reduce the burden of invasive pneumococcal diseases (IPD) 
and antimicrobial use, the 7-valent pneumococcal conjugate vaccine 
(PCV7, Prevenar
Ⓡ, Pfizer Inc, Philadelphia, PA, US) was developed 
and has been widely used in many countries. PCV7 was licensed 
in the US in February 2000, followed by Europe in 2001 and was 
introduced in Korea in November 2003. In the prevaccine era, the 
seven serotypes (4, 6B, 9V, 14, 18C, 19F and 23F) caused 80% of 
IPD in children in the US
2) and 54% of IPD in Korea, according to 
an analysis of isolates from a single hospital-wide surveillance
3). 
After the introduction of PCV7, the overall IPD decreased by 77% 
and IPD due to vaccine serotypes decreased by 99% in children < 
5 years age in the US
2). In the development of the pneumococcal 
conjugate vaccine, serotype 19F was chosen as the representative of 
serogroup 19 in anticipation that 19F would induce a cross-reactive 
immune response against serotype 19A
4). However, an increase in 
the proportion of IPD due to serotypes not included in the vaccine, 
especially 19A has been reported
5, 6). 
There are few reports regarding the cross-reactive immune response 
for serotype 19A after PCV7. In a previous report, antibodies against 
serotype 19A were elicited in healthy adult volunteers vaccinated with 
PCV7
7). However, in infants (7 months of age) vaccinated with 3 
doses of PCV7, opsonic antibodies to 19A were detected in only 19% 
of the subjects
8).
In this study, to determine the immune response of PCV7 against 
the vaccine-related serotype 19A in children, we evaluated the 
immune response to the vaccine serotype 19F and the vaccine-related 
serotype 19A in children aged 12-23 months of age. The immune 
response was compared among fully vaccinated subjects (3 primary 
doses and 1 booster dose), subjects only vaccinated with a primary 
series before 12 months of age (3 primary doses) and nonvaccinated 
subjects. Antibody titers against both serotypes were evaluated 
with the third-generation enzyme-linked immunosorbent assay 
(ELISA)
9, 10), and to examine the functionality of these antibodies, an 
opsonophagocytic killing assay (OPKA) was performed.
Material and methods
1. Subjects
A total of 45 subjects who visited Kangnam CHA Medical 
Center from September to December 2006 were included in this 
study. Study subjects were children aged 12-23 months who have 
been described previously
11). Residual serum samples from children 
who had blood sampling for medical examination were obtained 
after informed consent. Subjects were categorized according to 
their immunization status against PCV7 (Prevenar
Ⓡ, Pfizer Inc, 
Philadelphia, PA, US) into three groups as follows: 18 subjects with 
3 primary doses and 1 booster dose of PCV7 (booster group), 21 
subjects with 3 primary doses before 12 months of age (primary 
group), and 6 subjects with no vaccination history of PCV7 (control 
group). Children with underlying immunodeficiency disorders or 
history of blood transfusion, immunoglobulin or systemic steroid 
medication were excluded from the study.
The study protocol was approved by the Institutional Review 
Board of Kangnam CHA Medical Center and was conducted in 
accordance with the Declaration of Helsinki. Immunization status 
against PCV7 was confirmed by immunization records. 
2. ELISA for quantitative measurement of serotype 19F and 
19A specific antibodies 
Concentrations of antibodies against serotype 19F and 19A were 
determined by an ELISA using both C-polysaccharide and 22F 
serotype capsular polysaccharide absorption, as previously described
9, 
12). The ELISA was performed at the Center for Vaccine Evaluation 
and Study, Ewha Medical Research Institute at Ewha Womans 
University. In brief, the wells of a 96-well medium binding microtiter 
plate (Corning Inc., Corning, NY, US) were coated at 37°C for 5 
hours in a humidified chamber with 100 μ L of capsular PS 19F or 
19A (American Type Culture Collection [ATCC], Manassas, VA, 
US) diluted to a predetermined concentration. After being coated 
with the antigen, the plates were washed with 1 x Tris-buffered saline 
with 0.01% Brij 35 solution. All test sera were preabsorbed with 
C-polysaccharide (C-PS) (Statens Serum Institut, Copenhagen, 
Denmark) and 22F capsular PS (ATCC), and the reference standard 
89-SF (provided by Carl Frasch, Center for Biological Evaluation 
and Review, Food and Drug Administration, Bethesda, MD, US) 
was preabsorbed with C-PS. Sera were serially diluted 2.5-fold in 
absorption solution and incubated at room temperature (RT) for 
30 minutes. After incubation, samples were added to wells, titrated 
and incubated for 2 hours at RT. The wells in the plates were washed 
and incubated with alkaline phosphatase-conjugated goat anti-
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of the enzyme in each well was determined with p-nitrophenyl 
phosphate powder (Sigma, St. Louis, MO, US) in diethanolamine 
buffer (Sigma, Yong-in city, Gyungi-do, Korea). The optical 
density was measured at 405 nm and the optical density of 690 
nm was subtracted. Optical densities were converted to antibody 
concentrations using the CDC software for pneumococcal ELISA 
(written by Brian Plikaytis at the Centers for Disease Control and 
Prevention, Atlanta, GA, US). It can be downloaded free of charge 
from www.cdc.gov/ncidod/dbmd/bimb/elisa.htm). A detailed 
protocol can be found at www.vaccine.uab.edu.
3. OPKA for qualitative measurement of serotype 19F and 
19A specific antibodies
The opsonic activities of the samples were evaluated using the 
OPKA as previously described
13-16). In brief, target pneumococci were 
washed with opsonization buffer (Hanks’ balanced salt solution with 
Mg/Ca, 0.1% gelatin, and 10% fetal bovine serum) by centrifugation, 
and diluted to the proper bacterial density. Target strains of serotype 
19F and 19A were reported
13, 14). Bacterial suspensions were pooled in 
equal volumes. Serum samples were incubated before serial dilutions 
in opsonization buffer at 56°C for 30 minutes. Serum samples were 
diluted 5-fold before analysis due to limited amount of sera. Serially 
diluted serum (20 μ L/well) was mixed with 10 μ L of bacterial 
suspension in each well of round bottom 96-well plates (Corning 
Inc.). After a 30-minute incubation at RT with shaking (mini 
orbital shaker, Bellco Biotechnolgy, Vineland, NJ, US) at 700 rpm, 
10 μ L of 3-4 week old rabbit complement (PelFreeze Biologicals, 
Rogers, Arkansas, US) and 40 μ L of differentiated HL60 cells (4×
10
5 cells) were added to each well. HL60 cells were differentiated 
to granulocytes by culturing in RPMI-1640 with 10% fetal bovine 
serum and 1% L-glutamine and 0.8% dimethylformamide at a 
starting density of 4×10
5 cells/mL for 5 days. Plates were incubated 
in a tissue culture incubator at 37°C, 5% CO2 with shaking at 700 
rpm. After 45-minute incubation, plates were placed on ice for 10-
15 minutes and the final reaction mixture (10 μ L) was spotted onto 
THY agar plates (Todd-Hewitt broth with 0.5 % yeast extract and 
1.5% agar). After the mixture was absorbed into the agar, an equal 
volume of overlay agar (THY with 0.75% agar and 25 mg/L of 2, 3, 
5 -triphenyltetrazolium chloride) containing one of the antibiotics 
(spectinomycin or trimethoprim) was applied to each THY agar 
plate
17). After an overnight incubation at 37°C, the number of 
bacterial colonies in the agar plates was enumerated. Opsonic indices 
were defined as the serum dilution that kills 50% of bacteria and were 
determined by linear interpolation. The lower limit of detection in the 
5-fold serum dilution assay was 20. A detailed protocol is posted on a 
website (www.vaccine.uab.edu). 
4. Statistics
Anti-pneumococcal IgG antibodies and opsonic indices were 
transformed to a logarithmic scale and determined in geometric mean 
antibody concentrations (GMC) and geometric mean opsonic indices 
(GMI), respectively. Serum samples with opsonization indices of <20 
were assigned a value of 10 for analysis purposes. The proportion of 
subjects of ≥0.35 μ g/mL and opsonic indices ≥20 were determined, 
respectively. The χ
2 test was used to compare proportions; this test 
was replaced by the Fisher’s exact test when necessary. Antibody 
concentrations and opsonic indices were compared using the 2-tailed 
Student’s t test. 
Results
1. Characteristics of the subjects
The booster group consisted of 18 subjects. The mean age of 
the subjects was 18.8 months (range 16-23 months) and the mean 
interval between last vaccination and sampling was 3.3 months (range 
1-7 months). The primary group consisted of 21 subjects and the 
mean age was 13.9 months (range 12-16 months). The mean interval 
between the last vaccination and sampling was 7.2 months (range 4-9 
months). There were six subjects in the control group with a mean age 
of 14 months (range 12-16 months).
2. Immune response to 19F and 19A
1) Booster group
The GMCs in the booster group were higher for 19F than for 
19A (10.68 μ g/mL vs 5.75 μ g/mL, P<0.05). The GMIs were also 
significantly higher for 19F compared with 19A (3,124 vs 172, 
P<0.05). All subjects reported antibody concentrations ≥0.35 μ g/mL 
for both serotypes, whereas 100% and 61.1% showed opsonic activity 
for 19F and 19A, respectively (Table 1).
2) Primary group
In the primary group, the GMCs did not differ between the two 
serotypes; however, the GMIs were higher for 19F compared with 
19A (54 vs 15, P<0.05). Although all subjects had a titer of ≥0.35 μ g/
mL for both serotypes, only 66.7% and 19.0% of the subjects showed 
opsonic activity against 19F and 19A, respectively (Table 1). 
3) Control group
There was no difference in GMCs and GMIs between the 
serotypes 19F and 19A. Subjects with antibody concentrations ≥0.35 
μ g/mL were 83.0% for 19F and 66.7% for 19A. However none of 
the subjects in this group showed functional opsonic activity against 
these two serotypes (Table 1).
4) Immune response according to vaccination status
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compared with the primary and control groups (P<0.05). For 
serotype 19A, the antibody concentration also increased according 
to vaccination status (control group< primary group< booster group, 
P<0.05). Although the GMIs showed no significant difference 
against serotype 19A between the control group and primary group, 
GMIs were significantly higher in the booster group compared 
with the primary group. Among subjects in the booster group, 
subjects with very high opsonic titers for serotype 19A were observed. 
Therefore, after vaccination with PCV7, although subtle cross-
reactive immunity was noted against 19A in the primary group 
(19%), the response was augmented with a booster dose (61.1%); 
this cross-reactive immune response was significantly higher in the 
booster group (P<0.05) (Table 1, Fig. 1). This difference in immune 
response according to vaccination status can be seen well in the 
reverse cumulative distribution curve (Fig. 2). The graph shows that 
subjects who were vaccinated with a booster dose of PCV7 not only 
had a higher opsonic index for 19F, but also for 19A compared with 
those only vaccinated with the primary series. This is also seen in a 
comparison of the primary group and control group. 
Another important finding is that when evaluating the immune 
response with the ELISA, subjects with a higher antibody titer for 
serotype 19F also showed high antibody titers for serotype 19A. Thus 
we can consider an immune response is elicited against serotype 19A 
after vaccination. However, according to the OPKA, many subjects 
with high opsonic indices against 19F showed nondetectable functional 
antibody for serotype 19A. Although all of the subjects in the primary 
and booster group had anti-19A IgG titers ≥0.35 μ g/mL, only 61.1% 
Table 1. Immune Response to Pneumococcal Serotypes 19F and 19A according to Vaccination Status with 7-valent Pneumococcal Conjugate Vaccine
Booster (N=18) Primary (N=21) Control (N=6)
19F 19A 19F 19A 19F 19A
ELISA GMC (µg/mL) 10.68*
, † 5.75
† 1.50 1.60 0.98 0.58
95% CI 6.70‒17.10 3.70‒9.00 1.10‒2.10 1.20‒2.10 0.41‒2.36 0.24‒1.43
%≥0.35 µg/mL 100 100 100 100 83.0 66.7
OPKA GMI 3,124*
, † 172
† 54
† 15 10 10
95% CI 1,539‒6,342 51‒580 29‒103 10‒23 NA NA
% ≥ 20 100*
, † 61.1
† 66.7* 19.0 0 0
*P<0.05, 19F vs 19A
†P<0.05, Booster group vs Primary group or Control group
Abbreviations: N, number; ELISA, enzyme linked immunosorbent assay; OPKA, opsonophagocytic killing assay; GMC, geometric mean antibody concentration; 
GMI, geometric mean opsonic indices; CI, confidence interval. 
Fig. 1. Comparison of anti-19F IgG and anti-19A IgG measured by ELISA (A) and opsonophagocytic killing assay 
(B) in children immunized with primary and booster doses (Booster group ♦), primary doses (Primary group ●) of 
7-valent pneumococcal conjugate vaccine and no vaccination (Control group ▲).
Fig. 2. Reverse cumulative distribution curves of opsonic indices 
against 19F and 19A according to vaccination status with 7-valent 
pneumococcal conjugate vaccine. Children immunized with primary and 
booster doses (Booster group ♦), primary doses (Primary group ●) of 
7-valent pneumococcal conjugate vaccine and no vaccination (Control 
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and 19.0% had opsonic activity against serotype 19A, respectively. 
Therefore, among antibodies against serotype 19A detected by 
ELISA, a substantial proportion of these antibodies are nonfunctional 
antibodies which cannot be detected by OPKA.
Discussion
In this study we evaluated the quantitative and qualitative immune 
responses against vaccine type 19F and vaccine-related 19A according 
to immunization status with PCV7 in children aged 12-23 months. 
We found minimal quantitative and qualitative immunity against 
serotypes 19F and 19A in nonvaccinated control subjects. However 
in subjects previously vaccinated with 3 doses of a primary series of 
PCV7, 66.7% showed opsonic activity against serotype 19F and 
19.0% had opsonic activity against 19A at the age of 12-23 months. 
In addition, after 4 doses (including booster) of PCV7, 100% and 
61.1% of the subjects had opsonic activity against serotypes 19F and 
19A, respectively. From this we can speculate that after vaccination 
with PCV7, an immune response is elicited not only against vaccine 
type serotype 19F, but there is a weak cross-reactive immune response 
against serotype 19A after a primary series of 3 doses in infants and 
this response is amplified after a booster vaccination. 
The importance of the booster dose has been recently do-
cumented
18). In immunogenicity studies based on infants vaccinated 
with three primary doses of PCV7, opsonic antibodies against 
serotype 19A are reported in 3-19%
8, 19). One study evaluated the 
opsonic response after three primary doses as well as after one booster 
dose of PCV7 in the same subjects
20). In that particular study, 
although only 3.4% of the subjects showed opsonic activity after the 
primary series 27.6% had functional activity after the booster dose. 
Clinical data has accumulated highlighting an increase in IPD due 
to serotype 19A
2, 3, 5, 21). There are many theories regarding the increase 
of serotype 19A including vaccine-induced serotype replacement, 
secular trends, new clones and antibiotic pressure
22). Reinert et al.
22) 
speculated that highest rates of serotype 19A were found in countries 
with high antibiotic use (e.g., US, Spain and France) and countries 
with relatively low rates of antibiotic resistance (e.g., Norway and 
Germany) have a relatively stable incidence of disease due to 19A, 
despite the wide use of PCV7. Hausdorff et al.
18) reported that the 
possibility of an increase in incidence of IPD due to 19A coincided 
with a shortage of PCV7 in the US between 2001 and 2004, 
resulting in many children receiving fewer than three primary doses 
and/or no booster dose. However in regions with high antibiotic 
resistance, disease due to 19A has increased. Whether PCV7 had an 
effect in lowering the slope of increase is currently unknown. 
In this study the ELISA and OPKA were both performed to 
evaluate the immune response against PCV7 for a vaccine type 
serotype and vaccine-related serotype. However we found a sub-
stantial proportion of subjects with antibody titers ≥0.35 μ g/mL 
with no detectable opsonic activity. This finding has been previously 
reported for serotype 19F. OPKA seropositivity (86%) was a better 
predictor of IPD efficacy than ELISA (99%). Therefore, some sera 
seropositive with ELISA are negative in the OPKA
15). In this study, 
this discrepancy was more pronounced in the vaccine-related serotype 
compared with vaccine type serotype. Furthermore, more subjects of 
the primary or control group showed this compared with the booster 
group. OPKA correlates well with clinical effectiveness
15). Therefore, 
evaluation of immune response using the OPKA would be more 
desirable, especially for determining the immune status in relatively 
weak immune responses such as those of infants, nonvaccinated 
or immunosuppression subjects and evaluation of vaccine-related 
serotypes.
This study has some limitations. Blood sampling was not done 
prospectively after vaccination, therefore there was a deviation in 
the interval from vaccination to blood sampling between subjects. 
Within each group, interval from vaccination ranged from 1-7 
months in the booster group and 4-9 months in the primary group, 
however there was no definite correlation related with interval 
and OPA titer within each group. The WHO criteria for licensing 
pneumococcal vaccines recommends to evaluate immunogenicity 4 
weeks after a primary series
23). In regard, data presented in this study 
does not represent the immunogenicity to the PCV7, but rather gives 
us a mere insight towards the cross-reactive immune response. Also, 
samples were not obtained sequentially from the same subject after 
a primary and booster vaccination. Therefore difference in immune 
response among different subjects could be possible and this should 
be considered when interpreting the differences between the primary 
and booster results. There was no information regarding the subjects’ 
previous pneumococcal disease history or other routes of acquisition 
for immunity to pneumococcus. Therefore there is possibility that 
the data does not solely reflect the effect of the vaccination. To com-
pensate for this limitation, we included a group of nonvaccinated 
subjects as a control group, however there were a limited number of 
subjects in this group. Furthermore, in this study, due to a limited 
amount of sera, all samples were pre-diluted 5-fold, so the lower limit 
for opsonic activity was 20. The opsonic index which correlates with 
protection against IPD is 8
15, 19). Therefore the percentages of subjects 
with opsonic activity may be a under-estimation.
Protection against S. pneumoniae is based on serotype-specific 
antibodies. Hence, for a highly efficacious pneumococcal vaccine, it 
would be beneficial to include more serotypes. However this would 
lead to an increase in cost or possibly an increase in adverse events. 168      HJ Lee, et al. • Cross-reactive response to 19A after PCV7 vaccination
Another method for enhancing coverage against pneumococcal 
serotypes would be to use different conjugate methods or carrier 
proteins in the formula leading to elicit different degrees of immu-
nity including cross-reactive immunity for similar serotypes. The 
effect of a vaccine cannot be determined in a short time and many 
environmental and socio-economical factors should be considered. 
The results of this study give us a preliminary insight into the 
immune response for an important cross-reactive serotype 19A. 
However, continuous monitoring on the seroepidemiological 
changes of pneumococcus in clinical practices must coincide with the 
introduction of new vaccines.
In conclusion, in children 12-23 months age who were previously 
vaccinated with PCV7, a cross-reactive immune response is elicited 
in a small proportion of subjects against serotype 19A after a 
primary series of 3 doses and this response is amplified after booster 
vaccination. 
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